- Report
- September 2023
- 135 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- January 2024
- 169 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- July 2018
- 77 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- June 2022
- 135 Pages
Global
From €1737EUR$1,800USD£1,490GBP
€2172EUR$2,250USD£1,863GBP
- Report
- August 2022
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- January 2019
- 82 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- February 2020
- 163 Pages
Global
From €10612EUR$10,995USD£9,103GBP
- Report
- July 2022
- 225 Pages
Global
From €3475EUR$3,600USD£2,981GBP
Benlysta (belimumab) is a biologic drug used to treat systemic lupus erythematosus (SLE), an autoimmune disorder. It is the first and only FDA-approved treatment specifically for SLE. Benlysta works by blocking the activity of B-lymphocyte stimulator (BLyS), a protein that plays a role in the overactive immune response seen in SLE. It is administered as an intravenous infusion every four weeks.
The Benlysta market is composed of a range of companies that produce and distribute the drug. These include pharmaceutical companies such as GlaxoSmithKline, Human Genome Sciences, and Merck, as well as biotechnology companies such as Humanigen and BioCryst Pharmaceuticals. Additionally, there are a number of generic drug manufacturers that produce generic versions of Benlysta. Show Less Read more
